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Background: Bedside monitoring of cerebral blood flow (CBF) may provide new insights 
into the pathophysiology of brain injury, allow early detection of secondary ischemia, and 
help guide therapy. 
Objective: To evaluate a new brain tissue probe for serial CBF monitoring using near-
infrared spectroscopy Indocyanine green dye dilution (NeMo Probe) com- pared with the 
existing thermal diffusion probe (QFlow 500 Probe). 
Methods: In 7 pigs, the NeMo Probe and QFlow 500 Probe were inserted into the subcortical 
white matter. Parallel measurements were recorded during [1] baseline, [2] hypotension, [3] 
hypertension, and [4] hyperventilation. Thereafter, protocol points 1 through 4 were repeated 
once. The Spearman correlation (rs), Bland-Altman plot, concordance rate, and coefficient of 
variation were used for statistical analysis. 
Results: There was poor agreement between 56 pairs of absolute CBF values (rs = 0.52, P < 
.001). The mean bias was 10.7 ml/100 g/min with limits of agreement of 233.0 to·54.3 ml/100 
g/min. The analysis of 49 pairs of changes in CBF showed a good·correlation (rs = 0.83, P 
<.001), and the concordance rate was 93.3%. The coefficient of variation from repeated 
measurements under comparable physiological conditions was 51.6% for the QFlow 500 
Probe and 12.9% for the NeMo Probe. 
Conclusion: Absolute CBF values obtained with the NeMo Probe and QFlow 500 Probe 
cannot be interpreted as equivalent.  However, the NeMo Probe provides acceptable trending 
ability and reproducibility from repeated measurements, whereas the  reproducibility of the 
QFlow 500 Probe was poor. Future clinical studies are warranted to evaluate the NeMo Probe 
in the setting of acute brain injury. 
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Introduction 
Bedside monitoring of cerebral hemody- namics has allowed the identification of secondary 
ischemic events and new ther- apeutic approaches in patients with severe sub- arachnoid 
hemorrhage, stroke, and traumatic brain injury (1-4). Within the setting of multimodal 
neuromonitoring, determination of cerebral blood flow (CBF) is of particular importance 
because it is the key determinant of brain tissue oxygenation and glucose supply (5). 
Established bedside methods for CBF monitoring with inert tracers such as the nitrous oxide 
dilution method and xenon-133 dilution technique are technically difficult and time 
consuming and thus are not feasible in a neurointensive care unit (6, 7). 
In 2000, Vajkoczy et al (8) introduced a brain tissue probe (QFlow 500 Probe; Hemedex 
Inc, Cambridge, Massachusetts) for bedside assessment of CBF using the thermal diffusion 
method. The advantages of the probe include easy operating procedures, comparable to 
conventional intracranial pressure (ICP) probes, and continuous CBF measurements. The 
potential benefits have been documented in patients with aneurysmal subarachnoid 
hemorrhage (1). However, the clinical acceptance of the probe remains poor mainly 
because of methodological difficulties leading to significant measurement drifts (9, 10). 
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Recently, a new multiparametric brain tissue probe (NeMo Probe; NeMoDevices AG, 
Zurich, Switzerland) for ICP and brain temperature monitoring and for determination of 
cerebral hemodynamics and oxygenation has been developed (11). Whereas parameters of 
oxyhemoglobin and deoxyhemoglobin are measured continuously with near-infrared 
spectroscopy (NIRS), cerebral hemodynamic monitoring is based on a combined NIRS and 
indocyanine green (ICG) dye dilution method. After intravenous injection of ICG, the NeMo 
Probe facilitates serial measurements of the mean transit time of the dye (mttICG), 
cerebral blood volume (CBV), and CBF (12, 13). Previous studies have shown that ICG 
administration followed by near-infrared light exposure is safe when applied for CBF 
monitoring in animals with disrupted blood-brain barrier (14). In addition, preliminary case 
reports using scientific prototypes showed the feasibility and proof of concept of the NIRS-
ICG method in patients with acute brain injury (11, 15 16). 
In the present study, we evaluated the performance of the newly developed NeMo Probe 
compared with the existing QFlow 500 Probe in an experimental pig model allowing for 
standardized alterations of arterial blood pressure and oxygenation. 
 
Methods 
The Institutional Animal Care and Use Committee of the University Heidelberg approved the 
study (protocol No. 35-9185.81/G-47/14). The investigator-initiated experiment took place 
from August 9 to August 17, 2014, at the Interfakultäre Biomedizinische 
Forschungseinrichtung of the University Heidelberg. 
 
Measurement Technique 
The NeMo Probe is a conventional ICP and brain temperature probe additionally supplied 
with fibers for NIRS.16 Optical imaging with NIRS provides continuous monitoring of 
oxyhemoglobin and deox- yhemoglobin and serial measurements of CBF with the NIRS and 
ICG dye dilution method. The light source and detector electronics are included in the NeMo 
Control Unit (NeMoDevices AG). With the NIRS-ICG method, ICG (ICG-Pulsion; 
PULSION Medical Systems, Munich, Germany) in a dose of 0.3 mg/kg body weight is 
injected into a venous line followed by the injection of 10 mL of 5% glucose flush. The ICG 
dye dilution curve is recorded digitally, and the concentration of the dye is calculated with a 
bedside computer using preinstalled software (NeMo Monitor; NeMoDevices AG). CBF is 
calculated as the ratio of CBV to mttICG (CBF = CBV/mttICG) according to previously 
published algorithms.13 Repeated CBF measurements can be performed if clinically indicated 
because the recommended maximum daily dose of ICG is 5 mg/kg body weight. For 
comatose patients with severe brain injury in whom ICP probes are installed because of brain 
edema and intracranial hypertension, the NeMo Probe offers enhanced modality modes 
without an additional surgical procedure. The probe (5F diameter) is inserted into the 
subcortical white matter comparable to conventional ICP probes and secured with a 
conventional skull bolt kit. 
 
Anesthesia and Operative Procedure 
Seven male swine with an average weight of 29.2 kg (range, 25-33 kg) were anesthetized with 
Midazolam (5 mg/kg) and Azaperone (40 mg/kg) administered by intramuscular injection. 
Animals were orally intubated and mechanically ventilated (fraction of inspired oxygen 
[FiO2], 0.3). Anesthesia was maintained with 1.0% to 1.8% isoflurane inhalation. Capillary 
oxygen saturation was monitored from the ear with pulse oximetry. Body core temperature 
was maintained between 35.5°C and 37.0°C.  After surgical exposure of the right internal 
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jugular vein, a central venous catheter was inserted for administration of fluids and drugs. An 
arterial catheter was inserted into the femoral artery for continuous monitoring of mean 
arterial pressure (MAP) and arterial blood gas analysis. 
Both CBF probes (NeMo Probe and QFlow 500 Probe) were implanted into the left 
subcortical white matter through 2 burr holes placed 15 mm away from the midline and either 
over or 15 mm anterior to the coronal suture (probe tip distance, 10-20 mm). In addition, a 
conventional ICP probe (Neurovent-P; Raumedic AG, Helmbrechts, Germany) was inserted 
on the contralateral side through a burr hole 15 mm away from the midline and 15 mm 
anterior to the coronal suture. The NeMo Probe was secured with a skull bolt system (IM3, 
Licox; Integra LifeScience, Plainsboro, New Jersey), and the QFlow 500 Probe and ICP probe 
were anchored to the skin with a peripheral intravenous catheter and secured by sealing the 
burr hole with bone wax. 
 
Experimental Protocol 
Parallel measurements with the NIRS-ICG and thermal diffusion method were performed 
during baseline, as well as significant changes in arterial blood pressure and oxygenation 
parameters.  Automatically performed recalibrations of the QFlow 500 Probe (approximately 
every 30 minutes) were avoided for parallel measurements with the NIRS and ICG dye 
dilution method. After a stabilization phase of 60 minutes after probe insertion, [1] baseline 
values were obtained. Subsequent measurements were performed during the following 
maneuvers: [2] hypotension (Verapamil or Urapidil; MAP target ,60 mmHg for 10 minutes), 
[3] hypertension (norepinephrine; MAP target 110 mmHg for 10 minutes), and [4] 
hyperventilation (arterial partial pressure of carbon dioxide [PaCO2], 32 mmHg for 10 
minutes). Thereafter, after another stabilization phase of 60 minutes, protocol points 1 
through 4 were repeated. Between each challenge, a period of 20 minutes was allowed for 
parameter stabilization. A total of 8 NIRS-ICG measurements were performed in a single 
animal. 
 
Monitoring 
Measurement values obtained by the NIRS-ICG and thermal diffusion method were recorded 
with 2 bedside monitors (NeMo Monitor and Bowman Perfusion Monitor; Hemedex Inc). 
Relevant physiological parameters such as MAP and ICP were recorded continuously with an 
additional bedside monitor (MPR-2 log0 DATALOGGER; Raumedic AG, Helmbrechts, 
Germany). All monitors were synchronized before each experiment. Arterial blood gas 
analysis for determination of arterial partial pressure of oxygen (PaO2) and PaCO2 was 
performed before each measurement. 
 
Data Analysis and Statistics 
Statistical analysis was performed with Excel (version 14.5.5; Microsoft, Redmond, 
Washington) and Prism Graph software (Prism 5.0c GraphPad Software, Inc, La Jolla, 
California). Normal distribution of the data was tested with the Kolmogorov-Smirnov test. 
Results are presented as median and interquartile range unless otherwise indicated. 
Differences in measurement values between each experimental maneuver were analyzed with 
a paired t test. A value of P <.05 was considered statistically significant. Agreement between 
absolute CBF values (accuracy of measurements) was assessed with the Spearman correlation 
(rs) and Bland-Altman plot. A strong relationship between the parameters was defined as a 
correlation coefficient (rs value) ≥ 0.8. The Bland-Altman plot was used to assess the bias and 
limits of agreement by plotting the difference between both parameters against their mean. 
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Bias refers to the mean difference, and limits of agreement refer to the 95% confidence 
interval of the difference after correction for repeated measurements per animal (17). The 
ability to reliaby detected changes in CBF (ΔCBF) from consecutive measurements (trending 
ability) was assessed with the Spearman correlation and concordance rate. The difference 
from consecutive measurements with the same method was used to quantify ΔCBF. The 
concordance is the agreement of the direction of ΔCBF from consecutive measurements 
obtained by both methods expressed as the percentage of the total number of data points. 
Sufficient concordance was set to. 92% when values of ΔCBFQFlow,15% were excluded from 
analysis (central exclusion zone) (18). Reproducibility of the CBF measurements (precision of 
measurement values) was evaluated with the standard deviation and coefficient of variation 
from repeated measurements under comparable physiological conditions. The coefficient of 
variation was calculated as the ratio of the standard deviation to the mean (coefficient of 
variation = standard deviation/mean). Repeated measurements with changes in cerebral 
perfusion pressure. 10 mm Hg and PaCO2. 5 mm Hg were excluded from analysis. 
 
Results 
A total of 56 paired CBF measurements were analyzed in 7 animals. The observed ranges of 
measurement values obtained by both methods are shown in Table 1. Overall, CBFQFlow was 
by trend higher compared with CBFNeMo, but the difference was without statistical 
significance (P = .08). Median CBF values during each experimental maneuver are reported 
in Table 2. As shown, both methods demonstrated a significant drop in CBF during 
hypotension, an increase during hypertension, and a decrease again during hyperventilation. 
Median MAP and PaCO2 during the experiment are plotted in Figure 1. 
The accuracy of measurement values from 56 paired CBF measurements was analyzed with a 
scatterplot and a Bland-Altman plot (Figure 2). The correlation coefficient between absolute 
CBF values was rs = 0.52 (95% confidence interval, 0.29-0.69; P,.001). The mean bias of all 
CBF measurements (CBFQFlow 2 CBFNeMo) corrected for repeated measurements was 10.7 
ml/100 g/min with limits of agreement of 233.0 to 54.3 ml/100 g/min. 
The trending ability was assessed from 49 consecutive ΔCBF values (7 ΔCBF values in 7 
animals) with a 4-quadrant plot and concordance rate. The correlation coefficient between 
ΔCBFQFlow and ΔCBFNeMo was 0.83 (95% confidence interval, 0.70-0.90; P, .001; Figure 3). 
The overall concordance rate was 90.0% (44 of 49 pairs) and improved to 93.3% (42 of 45 
pairs when data sets with ΔCBFQFlow, 15% were excluded  
The reproducibility was analyzed from 28 repeated measurements under comparable 
physiological conditions (4 repeated measurements in 7 animals) using the standard deviation 
and coefficient of variation (Table 3). Repeated measurements with changes in cerebral 
perfusion pressure. 10 mm Hg or PaCO2. 5 mm Hg were excluded (n = 15). The coefficient of 
variation was 12.9% for CBF values obtained by the NeMo Probe and 51.6% for CBF 
measurements obtained by the QFlow 500 Probe. 
 
Discussion 
Previous studies have shown that large animals provide good- quality signals for the 
determination of cerebral hemodynamics and oxygenation with brain tissue probes (8, 19). In 
a pig model, we provide preliminary data on the performance of the newly developed NeMo 
Probe for serial CBF measurements compared with the existing QFlow 500 Probe offering 
continuous CBF monitoring. Absolute CBF values determined by both methods showed poor 
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agreement during standardized alterations in blood pressure and ventilation parameters. On 
the other hand, the NeMo Probe demonstrated acceptable trending ability and reproducibility 
of repeated measurements under comparable physiological con- ditions, whereas the 
reproducibility of the measurement values obtained with the QFlow 500 Probe was   poor. 
Accurate assessment of CBF is a major problem in unconscious patients in neurocritical care. 
So far, the QFlow 500 Probe is the only clinically established and validated monitoring 
system for bedside assessment of CBF.8 In contrast to the thermal diffusion probe facilitating 
continuous CBF measurements, the NeMo Probe provides serial CBF measurements after 
intravenous injection of ICG.13 In this study, we avoided injection of ICG during 
automatically performed recalibration phases of the QFlow 500 Probe (approximately every 
30 minutes) to obtain parallel measurements at each experimental maneuver. The results 
demonstrated poor agreement between absolute CBF values obtained by the 2 methods. In the 
scatterplot of CBFNeMo vs CBFQFlow, a large number of data points fell well below the line of 
identity (x = y), indicating that the NeMo Probe underreads the QFlow 500 Probe. This 
underreading was also demonstrated in the Bland-Altman plot in which the mean difference 
of both methods (CBFQFlow 2 CBFNeMo) was 10.7 ml/100g/min and the limits of agreement 
were inadmis- sibly high. Furthermore, there was an obvious sloping relation- ship between 
both methods, with a negative bias when CBF decreased and a positive bias when CBF 
increased. These findings clearly demonstrate that absolute CBF values obtained by the 
NeMo Probe cannot be interpreted as equivalent to those of the QFlow 500 Probe Reliable 
trending ability of CBF is an important issue for the clinical routine to guide therapy, whether 
it is detection of secondary ischemic events or guidance of therapeutic interven- tions. The 
ability of the NeMo Probe to track changes in CBF was analyzed by examination of the 
changes between consecutive pairs of CBF measurements taken before and during each 
experimental maneuver. The 4-quadrant plot of ΔCBFQFlow vs ΔCBFNeMo in our study showed 
a strong relationship (rs = 0.83). The concordance analysis demonstrated that the direction of 
ΔCBF of both methods agreed in 90.0% with all data sets, and agreement increased to 93.3% 
when data sets with ΔCBFQFlow ,15% were excluded from analysis. These findings suggest 
that suitable trending ability exists and are supported by previous studies reporting good 
agreement of cardiac monitoring systems when concordance was 92% after the exclusion of 
data with small changes caused by random effects (central exclusion zone) (20, 21). 
The reproducibility of measurement values under comparable physiological conditions is an 
important measure to assess the precision of hemodynamic monitoring devices. For this 
purpose, the standard deviation and coefficient of variation (equal to standard deviation/mean) 
were calculated. Kety and Schmidt6 reported repeated CBF measurements using the nitrous 
oxide method and found a standard deviation of 12 ml/100g/min under physiological 
conditions in healthy volunteers. Regional CBF monitoring using the xenon-133 dilution 
method revealed a coefficient of variation of 8.2% in patients with different neurological 
diseases such as migraine epilepsy, barbiturate intoxication, and brain injury.7 In the present 
study, repeated CBF measurements under comparable physiological conditions demonstrated 
a standard deviation of 2.4 ml/100g/min and a coefficient of variation of 12.9% when the 
NeMo Probe was used. Furthermore, the coefficient of variation for both CBVNeMo and 
mttICGNeMo was ≤ 10%, suggesting that the precision of measurement values is within 
acceptable limits. 
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Limitations 
Several limitations of this study need to be addressed. A major drawback is the lack of a gold 
standard for CBF measurements such as xenon-enhanced computed tomography as a 
reference method. Only comparison to a true gold standard would allow testing for the 
accuracy of absolute CBF values. The observed differences in the present study might be 
explained in part by methodological difficulties of the QFlow 500 Probe known to result in 
significant measurement drifts after recalibration phases and during monitoring cycles (CBF 
increase of 35% at the end of a 30-minute measurement cycle) (9, 10). This might have 
resulted in the observed excessively high coefficient of variation (51.6%) obtained by the 
QFlow 500 Probe in the present study. On the other hand, the algorithms applied to NIRS and 
ICG dye dilution, providing high precision of repeated measurements, might have also 
contributed to the observed underreading of CBF measurements. Therefore, further validation 
studies of both methods seem to be warranted in the future. Another important limitation is 
that we did not perform computed tomography after the experiment in each animal. 
Therefore, we cannot exclude theoretical sources of error such as probe location and 
microhemorrhages around the probe tip. Another limitation is that our data rely on a limited 
number of animals, and thus, the results of this study need to be interpreted as preliminary. 
The small sample size further limits the restriction of ΔCBF measurements to a predetermined 
band of interest to reduce sampling bias using concordance analysis. Finally, it is important to 
note that continuous monitoring data obtained by the NeMo Probe (ICP, brain temperature, 
oxyhemoglobin, and deoxyhemoglobin) were not part of this study. 
 
Conclusion 
This preliminary study demonstrates that absolute CBF values measured with the NeMo 
Probe cannot be interpreted as equivalent to the values measured by the existing QFlow 500 
Probe. On the other hand, the NeMo Probe offers acceptable trending ability during 
standardized changes in blood pressure and ventilation parameters, as well as acceptable 
reproducibility of measurement values from repeated measurements under comparable 
physiological conditions. Future clinical studies with multimodal neuromonitoring are 
warranted to evaluate the NeMo Probe in the setting of acute brain injury. 
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Table 1: Cerebral hemodynamic parameters obtained by QFlow 500 Probe and NeMo Probe from 56-paired measurements in 7 animals 
 
 QFlow 500 Probe NeMo Probe 
 median IQR min max median IQR min max 
CBF (ml/100g/min) 30.0 32.3 0.0 115.0 20.4 11.7 9.6 61.4 
CBV (ml/100g) - - - - 2.8 0.9 1.8 4.7 
mttICG (sec) - - - - 8.1 3.6 4.0 15.3 
 
CBF, cerebral blood flow; CBV, cerebral blood volume; mttICG, mean transit time of indocyanine green; IQR, interquartile range. 
Values are expressed as median and IQR 
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Table 2: Difference between cerebral blood flow (CBF) measurements obtained by QFlow 500 Probe and NeMo Probe during each experimental 
maneuver. 
 
 
Measurement Cycle 1 Measurement Cycle 2 
 Baseline Hypotension Hypertension Hyperventilation Baseline Hypotension Hypertension Hyperventilation 
CBFQFlow  
(ml/100g/min) 
27.0 (4.0) 19.0 (8.5) 52.0 (37.0) 15.0 (16.5) 48.0 (33.0) 9.0 (15.0) 58.0 (50.5) 13.0 (31.0) 
CBFNeMo  
(ml/100g/min) 
25.7 (8.5) 16.7 (3.1) 46.7 (17.2) 17.7 (3.1) 20.3 (4.3) 14.7 (6.5) 29.0 (9.4) 17.0 (6.5) 
p-value  0.5 0.003 0.002  0.02 0.01 0.001 
 
CBF, cerebral blood flow. Values are expressed as median and interquartile range. A-value of p <0.05 was considered statistically significant 
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Table 3: Standard deviation and coefficient of variation from 13 repeated measurements under comparable physiological conditions 
 
 CBFQFlow CBFNeMo CBVNeMo mttICGNeMo 
Mean (n=26) 23.8 ml/100g/min 21.1 ml/100g/min 3.0 ml/100g 9.7 sec 
Standard Deviation (n=26) 9.0 ml/100g/min 2.4 ml/100g/min 0.3 ml/100g 0.9 sec 
Coefficient of variation  (n=13) 51.6% 12.9% 10.2% 8.1% 
 
CBF, cerebral blood flow; CBV, cerebral blood volume; mttICG, mean transit time of indocyanine green 
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Figure 1: Mean arterial pressure (MAP) and arterial partial pressure of carbon dioxide 
(PaCO2) at each experimental maneuver in 7 animals. 
 
 
 
Values are expressed as median and interquartile range. *P ≤ .001 vs baseline 
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Figure 2: A, scatterplot for 56 paired cerebral blood flow (CBF) measurements with the NeMo Probe and QFlow 500 Probe. The solid line is the 
regression line; the dashed line is the line of identity (x = y). B, Bland-Altman plot of these paired values with the solid line at the bias (mean of the 
difference) and the dashed lines at 695% limits of agreement (standard deviation of the difference multiplied by 2). 
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Figure 3: Four-quadrant plot for 49 serial changes in cerebral blood flow (ΔCBF) using the NeMo Probe and QFlow 500 Probe. The solid line is  
the regression line; the dashed line is the line of identity (x = y). 
 
 
 
